Allogene Therapeutics Inc (ALLO) Gets a Buy Rating from William Blair

By Austin Angelo

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Allogene Therapeutics Inc (ALLOResearch Report). The company’s shares opened today at $26.09.

According to, Prasad is a 5-star analyst with an average return of 24.1% and a 62.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics Inc with a $39 average price target.

See today’s analyst top recommended stocks >>

Based on Allogene Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $30.51 million. In comparison, last year the company had a net profit of $0.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.